Raymond James Financial downgraded shares of INmune Bio (NASDAQ:INMB - Free Report) from a moderate buy rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.
Several other research analysts have also recently weighed in on INMB. BTIG Research restated a "neutral" rating on shares of INmune Bio in a research note on Tuesday. Scotiabank reissued a "sector underperform" rating on shares of INmune Bio in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.40.
Check Out Our Latest Report on INMB
INmune Bio Price Performance
INMB stock traded up $0.25 on Monday, reaching $2.61. 4,699,962 shares of the company traded hands, compared to its average volume of 778,332. The firm has a fifty day simple moving average of $6.98 and a 200-day simple moving average of $7.25. INmune Bio has a one year low of $1.89 and a one year high of $11.64. The company has a market cap of $61.43 million, a P/E ratio of -1.35 and a beta of 1.34.
INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). The firm had revenue of $0.05 million for the quarter. On average, sell-side analysts forecast that INmune Bio will post -2.24 EPS for the current year.
Institutional Trading of INmune Bio
Large investors have recently modified their holdings of the company. Quarry LP bought a new stake in shares of INmune Bio during the 1st quarter valued at about $48,000. Wells Fargo & Company MN boosted its holdings in shares of INmune Bio by 51.0% in the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after buying an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC bought a new stake in INmune Bio during the fourth quarter valued at approximately $48,000. JPMorgan Chase & Co. grew its position in INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after buying an additional 5,461 shares during the period. Finally, Focus Partners Advisor Solutions LLC purchased a new stake in INmune Bio during the first quarter valued at approximately $91,000. Institutional investors own 12.72% of the company's stock.
INmune Bio Company Profile
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
See Also
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
